Press Releases
UCB announces BRIVIACT now approved by FDA to treat partial-onset seizures in pediatric epilepsy patients
UCB announced that the U.S. FDA has approved a supplemental new drug application (sNDA) for the company’s newest anti-epileptic drug BRIVIACT CV oral formulations...
News
Boehringer Ingelheim R&D pushes to transcend disease boundaries
Family-owned pharmaceutical company Boehringer Ingelheim presented its latest pipeline updates at a Research & Development press conference entitled ‘Transcending Disease Boundaries’, at its global...
Clinical Trials
AstraZeneca provides update on GALATHEA Phase III trial for Fasenra in chronic obstructive pulmonary disease
AstraZeneca and MedImmune, its global biologics research and development arm, announced top-line results from the GALATHEA Phase III trial for Fasenra (benralizumab) in patients...
Press Releases
Novartis announces FDA approval of Gilenya as the first disease-modifying therapy for pediatric relapsing multiple sclerosis
Novartis announced that the US FDA has approved Gilenya® (fingolimod) for the treatment of children and adolescents 10 to less than 18 years of...
White Papers
Take a Closer Look at the Pharma Logistics Compliance Report!
This whitepaper covers the latest pharmaceutical logistics regulatory developments around the globe such as FMD, MHRA, ICH Q12, PACMP, GMP, DSCSA and more!. ...
Press Releases
ChargePoint Technology Launches First-of-its-kind Smart Monitoring Technology at ACHEMA 2018
Powder containment and aseptic transfer valve specialist, ChargePoint Technology, has launched a unique Smart monitoring hub to support efficiency and safety within chemical and...
Research Insight
Protagen AG collaborates with UCSF to study better immuno-profiling of cancer patients receiving immunotherapy
Protagen AG has announced the start of a collaboration with the University of California, San Francisco (UCSF) to utilize Protagen’s SeroTag® technology to investigate...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from up to 5 devices at once
Must read